PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29433086-7 2018 Pretreatment with the CCK1 receptor (CCK1R) antagonist SR 27897 and CCK2 receptor (CCK2R) antagonist L-365,260 attenuated anorexia induction by both CCK- and T-2 toxin in a dose dependent manner. l-365 101-106 cholecystokinin B receptor Homo sapiens 68-81 29433086-7 2018 Pretreatment with the CCK1 receptor (CCK1R) antagonist SR 27897 and CCK2 receptor (CCK2R) antagonist L-365,260 attenuated anorexia induction by both CCK- and T-2 toxin in a dose dependent manner. l-365 101-106 cholecystokinin B receptor Homo sapiens 83-88 10636070-7 1999 RESULTS: The cell line LN 36 responded with increased cell number to stimulation by gastrin-17 and decreased cell number to inhibition by the CCK-B receptor antagonist L-365,260. l-365 168-173 cholecystokinin B receptor Homo sapiens 142-156 16998832-15 2006 Overexpression of CCK2R by stable transfection of CCK2R plasmid amplified this increase and incubation with 1 microM L-365,260, a specific CCK2R antagonist, completely inhibited the effect of gastrin. l-365 117-122 cholecystokinin B receptor Homo sapiens 18-23 24385417-6 2014 Furthermore, the CCK1 receptor antagonist SR 27897 and the CCK2 receptor antagonist L-365,260 dose-dependently attenuated both CCK- and DON-induced anorexia, which was consistent with this gut satiety hormone being an important mediator of 8-ketotrichothecene-induced food refusal. l-365 84-89 cholecystokinin B receptor Homo sapiens 59-72 15655524-4 2005 Both these stimulating effects were abolished by L-365,260 or GV150013 (CCK-2 receptor antagonists), but were unaffected by SC-560 (COX-1 inhibitor). l-365 49-54 cholecystokinin B receptor Homo sapiens 72-86 7786960-0 1995 A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. l-365 30-35 cholecystokinin B receptor Homo sapiens 43-47 8928909-6 1996 Growth of BxPC-3 human pancreatic cancer cell in serum-free medium was inhibited by the addition of the CCK-B/gastrin receptor antagonist L-365,260, and gastrin treatment reversed the inhibitory effect of the antagonist. l-365 138-143 cholecystokinin B receptor Homo sapiens 104-109 9296353-5 1997 In contrast, the structurally similar CCK-B receptor antagonist L-365,260 [3R(+)-N-[2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin -3-yl]-N"-(methylphenyl)urea; 30 nM-10 microM] produced progressive rightward shifts in the CCK-4 concentration-response curve, with no effect observed on the CCK-4 maximum response. l-365 64-69 cholecystokinin B receptor Homo sapiens 38-52 7786960-4 1995 Therefore, the present multicenter, placebo-controlled, double-blind trial was designed to investigate the efficacy of L-365,260, a CCKB antagonist, in patients with panic disorder with or without agoraphobia. l-365 119-124 cholecystokinin B receptor Homo sapiens 132-136 8335062-6 1993 The selective non-peptide CCKB receptor antagonist L-365,260 was more potent than the selective CCKA receptor antagonist MK-329 in inhibiting the [Ca2+]i mobilization elicited by 10 nM CCK-8 with IC50 values of 20 +/- 8 nM and 400 +/- 100 nM, respectively. l-365 51-56 cholecystokinin B receptor Homo sapiens 26-30 10467593-2 1994 Here, we report that the memory-enhancing effect of the CCK-B receptor antagonist L-365,260 (1 mg/kg i.p. l-365 82-87 cholecystokinin B receptor Homo sapiens 56-70 8192551-1 1994 BACKGROUND: We investigated whether the selective brain cholecystokinin (CCKB) receptor antagonist, L-365,260, could antagonize the panicogenic effects of CCK-tetrapeptide (CCK-4) in patients with panic disorder. l-365 100-105 cholecystokinin B receptor Homo sapiens 50-87 8222496-0 1993 The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. l-365 32-37 cholecystokinin B receptor Homo sapiens 4-20 1728842-2 1992 This paper reviews experiments in which devazepide (a selective CCK-A receptor antagonist) and L-365,260 (a selective CCK-B-gastrin receptor antagonist) have been used. l-365 95-100 cholecystokinin B receptor Homo sapiens 118-123